The CLARITY study aims to look at the development of antibodies to SARS-CoV-2 (the virus that causes COVID-19) in UK patients with IBD.
Researchers will test samples from patients on different IBD drugs collected since the start of 2020 for antibodies against SARS-CoV-2. They will then also look at the outcomes of these patients over the next 12 months.
What to they hope to find out?
- Provide insights into which IBD patients are at risk of COVID-19 infection,
- Better understanding of the impact of IBD medications on developing protective antibodies against the virus,
- Build evidence about safer prescribing of immunomodulator and biologic drugs in the COVID-19 era,
- Inform public health policy on vaccination strategies.
Although this study will define risk in IBD patients, there are potentially important lessons to be learned for millions of patients across the UK with other immune mediated diseases treated with similar therapies.
The team would be really interested to hear from patients taking infliximab or vedolizumab to take part in this work. If you would like to get involved, please speak to your IBD team to see if your hospital is taking part.
More details are available on their website.
Start date: Summer 2020
When will the findings of this work come out? The results of these analyses should be ready in autumn/winter 2021.
Lead researcher: Dr Tariq Ahmad (Royal Devon & Exeter Hospital)